|Referral date||01 June 2007|
|Closing date for invited submissions / evidence submission:||TBC|
|1st appraisal committee meeting:||TBC|
|Assessment Group / Evidence Review Group:||TBC|
|Executive Lead:||Gillian Leng|
|14 May 2014||
As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of tolevamer for clostridium difficile..
Following an update on the regulatory status of this technology, the manufacturer has informed us that development on tolevamer for clostridium difficile has stopped and there are no plans to seek regulatory approval. Therefore, the appraisal remains suspended.
As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
For further information on our processes and methods, please see our CHTE processes and methods manual